146 related articles for article (PubMed ID: 8258997)
21. Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.
Masucci G; Wersäll P; Ragnhammar P; Mellstedt H
Cancer Immunol Immunother; 1989; 29(4):288-92. PubMed ID: 2665935
[TBL] [Abstract][Full Text] [Related]
22. The combination of interleukin-2 and interferon alpha effectively augments the antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2 against the colorectal carcinoma cell line HT29.
Bungard S; Flieger D; Schweitzer S; Sauerbruch T; Spengler U
Cancer Immunol Immunother; 1998 Jun; 46(4):213-20. PubMed ID: 9671144
[TBL] [Abstract][Full Text] [Related]
23. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.
Liljefors M; Nilsson B; Hjelm Skog AL; Ragnhammar P; Mellstedt H; Frödin JE
Int J Cancer; 2003 Jul; 105(5):717-23. PubMed ID: 12740924
[TBL] [Abstract][Full Text] [Related]
24. MAb17-1A and cytokines for the treatment of patients with colorectal carcinoma.
Frödin JE; Fagerberg J; Hjelm Skog AL; Liljefors M; Ragnhammar P; Mellstedt H
Hybrid Hybridomics; 2002 Apr; 21(2):99-101. PubMed ID: 12031098
[TBL] [Abstract][Full Text] [Related]
25. Colony-stimulating factor enhancement of myeloid effector cell cytotoxicity towards neuroectodermal tumour cells.
Baldwin GC; Chung GY; Kaslander C; Esmail T; Reisfeld RA; Golde DW
Br J Haematol; 1993 Apr; 83(4):545-53. PubMed ID: 7686031
[TBL] [Abstract][Full Text] [Related]
26. Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome--an important antitumoral effector function?
Frödin JE; Faxas ME; Hagström B; Lefvert AK; Masucci G; Nilsson B; Steinitz M; Unger P; Mellstedt H
Hybridoma; 1991 Aug; 10(4):421-31. PubMed ID: 1937495
[TBL] [Abstract][Full Text] [Related]
27. Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses.
Baxevanis CN; Tsavaris NB; Papadhimitriou SI; Zarkadis IK; Papadopoulos NG; Bastounis EA; Papamichail M
Eur J Cancer; 1997 Jul; 33(8):1202-8. PubMed ID: 9301443
[TBL] [Abstract][Full Text] [Related]
28. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.
Hernandez-Ilizaliturri FJ; Jupudy V; Reising S; Repasky EA; Czuczman MS
Leuk Lymphoma; 2005 Dec; 46(12):1775-84. PubMed ID: 16263581
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cytokines.
Flieger D; Spengler U; Beier I; Kleinschmidt R; Hoff A; Varvenne M; Sauerbruch T; Schmidt-Wolf I
Hybridoma; 1999 Feb; 18(1):63-8. PubMed ID: 10211790
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM-CSF.
Bianchi AC; Heslop HE; Veys P; Macey M; Holland M; Prentice HG; Brenner MK
Br J Haematol; 1989 Dec; 73(4):468-74. PubMed ID: 2692692
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors.
Ragnhammar P
Med Oncol; 1996 Sep; 13(3):167-76. PubMed ID: 9106176
[TBL] [Abstract][Full Text] [Related]
32. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF.
Wadhwa M; Skog AL; Bird C; Ragnhammar P; Lilljefors M; Gaines-Das R; Mellstedt H; Thorpe R
Clin Cancer Res; 1999 Jun; 5(6):1353-61. PubMed ID: 10389919
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma.
Kushner BH; Kramer K; Cheung NK
J Clin Oncol; 2001 Nov; 19(22):4189-94. PubMed ID: 11709561
[TBL] [Abstract][Full Text] [Related]
35. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases.
Müller H; Nakchbandi V; Chatzisavvidis I; von Voigt C
Hepatogastroenterology; 2003; 50(54):1919-26. PubMed ID: 14696433
[TBL] [Abstract][Full Text] [Related]
36. Immune changes in patients with colorectal cancer treated by adjuvant therapy with monoclonal antibody 17-1A: a pilot study.
Tsitsilonis OE; Tsavaris NB; Kosmas C; Gouveris P; Papalambros E
J Chemother; 2003 Aug; 15(4):387-93. PubMed ID: 12962368
[TBL] [Abstract][Full Text] [Related]
37. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A.
Fagerberg J; Ragnhammar P; Liljefors M; Hjelm AL; Mellstedt H; Frödin JE
Cancer Immunol Immunother; 1996 Feb; 42(2):81-7. PubMed ID: 8620524
[TBL] [Abstract][Full Text] [Related]
38. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
[TBL] [Abstract][Full Text] [Related]
39. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
40. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Murphy RF; Hamilton JM; Balis F; Steinberg S; Arbuck SG; Setser A; Jordan E; Chen A
J Clin Oncol; 1994 Mar; 12(3):560-8. PubMed ID: 8120554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
